NAD+ Injection: A Sourcing Guide for Licensed Practices
Short answer: NAD+ is nicotinamide adenine dinucleotide (nonproprietary name nadide), a pyridine nucleotide coenzyme with molecular formula C21H27N7O14P2 and a molecular weight of about 663.4 g/mol (PubChem CID 5892, CAS 53-84-9) (PubChem). It isn't a peptide, but clinics source it the same way: as a lyophilized powder in a sealed vial. FDA's current 503A nominations list puts Nicotinamide Adenine Dinucleotide (NAD) in category 1 (under evaluation) (FDA). Biomed Peptides lists NAD+ 500 mg and NAD+ 1000 mg vials for verified, licensed providers only.
This guide covers sourcing for NAD+ injection supplies: identity, regulatory context, vial formats, storage, injection vs. IV logistics, and supplier checks. It doesn't cover administration or patient selection. Those decisions belong to the prescriber.
What is NAD+?
Identity and names
PubChem lists NAD+ under the title nadide, with synonyms including β-NAD, coenzyme I, diphosphopyridine nucleotide (DPN), and nicotinamide adenine dinucleotide (PubChem). Structurally, it's two nucleotides joined through a diphosphate bridge: one carries adenine, the other carries a nicotinamide (3-carbamoylpyridinium) ring, as shown in PubChem's systematic name.
Sigma-Aldrich's product sheet describes β-NAD as "a pyridine nucleotide" and "a coenzyme necessary for the catalytic reaction of certain enzymes," which acts as "a carrier for hydride ion, forming β-NADH" (Sigma-Aldrich). That's the biochemistry behind the "+": NAD+ is the oxidized form, and NADH is the reduced form.
| Attribute | Value |
|---|---|
| Name | Nicotinamide adenine dinucleotide (NAD+) |
| Nonproprietary name | Nadide |
| Common synonyms | β-NAD, coenzyme I, DPN |
| Classification | Pyridine nucleotide (dinucleotide), not a peptide |
| Molecular formula | C21H27N7O14P2 |
| Molecular weight | ≈663.4 g/mol |
| CAS (as listed in PubChem) | 53-84-9 |
| PubChem | CID 5892 |
Regulatory context: NAD and its forms on FDA's 503A list
Under section 503A, a bulk drug substance generally has to have a USP or NF monograph, be a component of an FDA-approved drug, or appear on FDA's 503A bulks list. FDA also requires a valid certificate of analysis (COA) and an FDA-registered (section 510) manufacturing establishment (FDA).
FDA's list of substances nominated under 503A (updated May 14, 2026) treats different forms separately (FDA nominations list):
| Entry on FDA's list | Category |
|---|---|
| Nicotinamide Adenine Dinucleotide (NAD) | Category 1: Under Evaluation |
| Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH) | Category 1: Under Evaluation |
| Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate | Category 3: Nominated Without Adequate Support |
FDA says it doesn't intend to take action against a compounder for using a category 1 substance "provided that the conditions described in the guidance document are met" (FDA). Because form and salt matter on that list, make sure the COA names the exact form supplied. Category 1 isn't the same as being on the final 503A bulks list, and these pages change, so confirm current status with your compounding pharmacy.
How NAD+ is supplied to clinics
500 mg and 1000 mg lyophilized vials
The Biomed Peptides lyophilized catalog lists:
- NAD+ 500 mg
- NAD+ 1000 mg
Vial strength is the amount of NAD+ in the sealed vial. Pick the strength that fits the prescriber's orders and your vial-use policy, and make sure the vial label, the COA, and your records all show the same strength.
Storage and handling
Always follow the product label first. For background on how the molecule behaves, Sigma-Aldrich's β-NAD product sheet says (Sigma-Aldrich):
- β-NAD "is very hygroscopic and should be stored desiccated" at –20 °C.
- Solutions "are rapidly degraded upon heating" and are "very labile in alkaline solutions, especially in the presence of phosphate, maleate, or carbonate."
- Solutions "are also sensitive to light."
In practice: keep sealed vials dry, cold, and dark; let a cold vial reach room temperature before opening so moisture doesn't condense on the powder; and treat any reconstituted vial as short-life inventory with its own label and beyond-use date. For opened multi-dose vials, CDC (citing USP <797>) says to date the vial and discard it within 28 days unless the manufacturer states another date (CDC). Our lyophilized peptides storage guide applies to NAD+ vials too.
NAD injection vs IV: a logistics comparison
Searches for "nad injection vs iv" usually come from practices deciding how to stock and staff. This comparison is about format and workflow only. The route is the prescriber's call.
| Injection workflow | IV workflow | |
|---|---|---|
| Starting material | Lyophilized NAD+ vial | Lyophilized NAD+ vial |
| Preparation | Reconstitute and draw up per the order | Reconstitute, then add to an infusion bag per the order |
| Supplies | Diluent, syringes, needles | Diluent, IV fluid, administration sets, catheters, pump if used |
| Space and staff | Medication prep area, exam room | Medication prep area, infusion chair, staff for the infusion |
| Compounding standards | Follow your sterile prep policies | Admixing typically falls under USP <797> |
On that last row: CDC notes that USP <797> defines sterile compounding as "combining, admixing, diluting, pooling, reconstituting, repackaging or altering a drug or bulk drug substances to create a sterile medication" (CDC). Talk with your compounding pharmacy about which preparations it should handle. For either workflow, CDC recommends drawing up medications "in a designated clean medication preparation area" and preparing injections as close as possible to administration (CDC).
The "best NAD injection on the market": how practices evaluate suppliers
There's no objective "best NAD injection on the market." What practices can evaluate is the supplier. Use the same checks you'd use for any peptide wholesale supplier:
- Exact form named. The COA should say NAD+ (nadide), not just "NAD," and not a different salt or the reduced form unless that's what you ordered.
- Lot-specific COA. Identity, purity by HPLC, and assay, with the lot number matching the vial. See our peptide COA and third-party testing guide.
- Endotoxin results where applicable.
- Manufacturer and site information, since 503A requires a section 510-registered establishment for bulk drug substances (FDA).
- Labeled storage and expiration that reflect the hygroscopic, moisture-sensitive nature of the product.
- Provider verification. A supplier that checks licensure before selling is a supplier built for clinical accounts.
Order NAD+ for your practice
Biomed Peptides supplies physician-use product only to licensed healthcare providers. We don't sell to patients or consumers. Apply for provider access to view NAD+ 500 mg and 1000 mg pricing and COAs, or browse the lyophilized catalog to plan your formulary.
FAQ
What is NAD+?
NAD+ is nicotinamide adenine dinucleotide (nadide), a pyridine nucleotide coenzyme. PubChem lists its molecular formula as C21H27N7O14P2 and its molecular weight as about 663.4 g/mol (CID 5892). It isn't a peptide.
What is NAD's status on FDA's 503A list?
FDA's 503A nominations list (updated May 14, 2026) names Nicotinamide Adenine Dinucleotide (NAD) and NADH disodium in category 1, under evaluation, while Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate is in category 3. Confirm current status with your compounding pharmacy.
What NAD+ vial sizes does Biomed Peptides carry?
The catalog lists NAD+ 500 mg and NAD+ 1000 mg lyophilized vials.
What's the difference between NAD injection vs IV for a clinic?
Both start from the same lyophilized vial. IV adds an infusion bag, administration sets, chair time, and an admixing step that typically falls under USP <797>. The route is the prescriber's decision.
How should NAD+ vials be stored?
Follow the product label. NAD+ is very hygroscopic, so keep vials sealed, dry, cold, and protected from light, and let a cold vial reach room temperature before opening.
Sources
- PubChem. Nadide (CID 5892). https://pubchem.ncbi.nlm.nih.gov/compound/5892
- Sigma-Aldrich. β-Nicotinamide adenine dinucleotide sodium salt (N0632), Product Information. https://www.sigmaaldrich.cn/deepweb/assets/sigmaaldrich/product/documents/206/486/n0632pis-mk.pdf
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026). https://www.fda.gov/media/94155/download
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- CDC. Preventing Unsafe Injection Practices (Injection Safety, for healthcare providers). https://www.cdc.gov/injection-safety/hcp/clinical-safety/
Frequently Asked Questions
Quick answers related to this article.